To evaluate the mechanisms that facilitate patient access to orphan drugs (ODs) in Australia, Canada and Sweden and recent examples of their application.
HTA outcomes for recently-evaluated ODs
Two oncology ODs have recently been evaluated in Australia, Canada and Sweden: Gazyvaro/Gazyva ® (Roche) and Imbruvica ® (Janssen), both indicated for the treatment of chronic lymphocytic leukaemia (CLL). Table 3 summarises the outcomes of their HTAs in the three countries. Further details are presented below.
Sweden (Tandvårds-och läkemedelsförmånsverket TLV)
• Although there are no specific HTA processes for ODs in Sweden, there is flexibility in the decision-making process guided by three principles which means a higher cost per QALY can be accepted when the disease severity is high or if there are few other treatments to choose from (TLV 2014):
• To assist introduction of novel cancer therapies across the county councils, the Swedish Council Novel Therapies evaluates willingness-to-pay (giving disease severity the highest weighting), makes recommendations on novel drugs, and negotiates pricing to guarantee the same price for a cancer drug used in hospitals all over the country (Mellstedt & Frodin 2016) .
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Results
• Currently none of these countries have specific HTA processes for ODs at a national level, although some Canadian provinces have OD-specific reimbursement programmes and Ontario has a specific OD evaluation framework.
• Instead, additional 'safety net' processes (Australia, Canada) or flexibility in the usual process (Sweden) are used to provide opportunities to allow access to ODs. • However, these processes and decisions vary substantially between countries.
For these oncology OD examples, positive recommendations were given in Canada and Sweden, whereas neither was reimbursed in Australia. However, differences in provincial decision-making processes may result in regional disparities in Canada • Understanding the range of approaches available can help individual healthcare systems continue to reduce uncertainties in decision making processes and provide equitable access to oncology ODs. • Funding for clinically-effective "ultra orphan" life-saving drugs failing to meet cost-effectiveness criteria • The drug must meet eight strict criteria, including the rarity and severity of the disease, lack of alternative treatments, and evidence that the drug will substantially extend the patient's lifespan • Specific patient eligibility criteria and ongoing monitoring requirements must also be met (DoH 2016).
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Canada (Canadian Agency for Drugs and Technologies in Health, CADTH)
• Despite no national-level specific HTA process for ODs, 5/10 Canadian provinces have established specific processes for OD reimbursement: Alberta, British Columbia, New Brunswick, Ontario, and Saskatchewan (CADTH 2016).
• This has resulted in disparities in access to publicly funded ODs across Canada (Menon et al. 2015 ).
• Federal, provincial and territorial governments have begun to examine ways to address issues and costs around ODs collaboratively using evidence-based approaches (Canadian Intergovernmental Conference Secretariat 2015) (Menon et al. 2015) . These may build on current practices around managed entry/exit criteria, coverage with evidence building, and risk sharing (Wong-Rieger 2015) . • Imbruvica ® : not recommended because the population and clinical place were not adequately defined, comparative clinical benefit couldn't be quantified, and the cost-effectiveness and financial implications were underestimated and unacceptably high (PBAC 2015).
• Imbruvica ® : recommended conditional on the costeffectiveness being improved, but advised provinces to consider pricing arrangements/ cost structures to improve costeffectiveness (CADTH 2015b).
• Imbruvica ® : recommended for reimbursement as it was considered costeffective (TLV 2015a).
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